Brief: Nurix Therapeutics Reports Case Study Of Patient With Aggressive Non-Hodgkin’S Lymphoma (Nhl) Showing A Complete Clinical Response To Nx-2127 At The 5Th Annual Targeted Protein Degradation (Tpd) Summit

Nurix Therapeutics

26/10/2022 12:02

Oct 26 (Reuters) - Nurix Therapeutics Inc  NRIX.O :
    * NURIX THERAPEUTICS REPORTS CASE STUDY OF PATIENT WITH
AGGRESSIVE
NON-HODGKIN’S LYMPHOMA (NHL) SHOWING A COMPLETE CLINICAL
RESPONSE TO NX-2127 AT THE 5TH ANNUAL TARGETED PROTEIN
DEGRADATION (TPD) SUMMIT
    * NURIX THERAPEUTICS INC - COMPLETE RESPONSE OBSERVED AND
ONGOING
IN A PATIENT WITH MULTIPLY RELAPSED/REFRACTORY DIFFUSE LARGE B
CELL LYMPHOMA (DLBCL)
    * NURIX THERAPEUTICS INC - DUAL BTK DEGRADATION AND
IMMUNOMODULATORY ACTIVITY ACHIEVED BY DAY 8 AND ASSOCIATED WITH
CONFIRMED COMPLETE RESPONSE AT FIRST CLINICAL ASSESSMENT
    * NURIX THERAPEUTICS INC - CLINICAL ACTIVITY IS CONSISTENT
WITH
POTENTIAL SYNERGY OF NX-2127 DUAL MECHANISM OF ACTION
    * NURIX THERAPEUTICS INC - TREATMENT WITH NX-2127 WAS WELL
TOLERATED WITH AN ADVERSE EVENT PROFILE CONSISTENT WITH PREVIOUS
CLINICAL DISCLOSURES

Source text for Eikon:  ID:nGNX4PnRZV 
Further company coverage:  NRIX.O 
 ((Reuters.Briefs@thomsonreuters.com;))